Latest Vascular endothelial growth factor Stories
A major medical discovery by scientists at The University of Nottingham could lead to the development of an entirely new type of painkiller.
A single ILUVIEN implant provides treatment for three years ATLANTA, Sept. 29, 2014 /PRNewswire/ -- Alimera Sciences, Inc.
TARRYTOWN, N.Y., Sept. 22, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd.
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept.
Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
TARRYTOWN, N.Y., Sept. 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd.
SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"),
- A woman chauffeur.
- A woman who operates an automobile.